 Citi has raised the price target on Galera Therapeutics Inc NASDAQ:GRTX to 20 suggesting 361 upside from 11 and maintained a Buy rating. Analyst Yigal Nochomovitz is re-introducing avasopasem with a 90 probability of success into his revenue model following the recent stunning disclosure that Galera discovered an error in their computer code used to compute the statistical significance of the primary endpoint in the ROMAN Phase 3 trial. 